Undisclosed Retinal Program(s)

About Nanoptima

NanOptima is a private, pre-revenue biotech developing novel controlled-release drug depots for retinal diseases, operating from Alderley Park in Cheshire, UK. The company's core mission is to alleviate the unsustainable demand on healthcare systems like the NHS caused by the need for frequent intravitreal injections by creating long-acting alternatives. While specific pipeline details are not publicly disclosed, its technology platform targets a significant unmet need in ophthalmology. The company appears to be in a pre-clinical or early development stage, positioning itself in a competitive but high-growth market segment.

Therapeutic Areas